Volume 7, Issue 2 (May 2019)
Res Mol Med (RMM) 2019, 7(2): 33-38 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Namazi F, Hadi N, Parnian F, Moghimi M. Evaluation of IL-2 and IL-7 expression in patients with prostate cancer. Res Mol Med (RMM) 2019; 7 (2) :33-38
URL: http://rmm.mazums.ac.ir/article-1-321-en.html
URL: http://rmm.mazums.ac.ir/article-1-321-en.html
1- Medical Biotechnology Research Center, Ashkezar Branch, Islamic Azad University, Ashkezar, Yazd, Iran
2- Medical Genetics Research Center of Genome, Mohtasham St., Isfahan, Iran.
3- Medical Biotechnology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4- Associate Professor of Clinical and Surgical pathology, Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , mansour_moghimi@yahoo.com
2- Medical Genetics Research Center of Genome, Mohtasham St., Isfahan, Iran.
3- Medical Biotechnology, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4- Associate Professor of Clinical and Surgical pathology, Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , mansour_moghimi@yahoo.com
Abstract: (4871 Views)
Background: Prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of cancer-related deaths in men worldwide. Interleukins (ILs) display required inflammation moderator. IL-2 and IL-7 play significant roles in regulating cancer-immune system interactions. So, the purpose of this investigation was to evaluate the expression level of IL-2 and IL-7 in prostate cancer patients and healthy subjects.
Materials and methods: In this case-control study, expression of IL-2 and IL-7 was examined in peripheral blood of 40 prostate cancer patients and 40 healthy subjects by reverse transcription quantitative real-time polymerase chain reaction.
Results: Our findings showed that IL-7 has highly elevated expression in patients with prostate cancer compared to healthy subjects (p-value = 0.0001). In contrast, no significant difference was observed in the expression of the IL-2 between the two study groups (p-value = 0.12).
Conclusions: Based on the results, IL-7 may be used as a prospective biomarker or as a molecular target in designing new prostate cancer control strategies. However, the findings of this investigation revealed no association between IL-2 expression and prostate cancer. Nevertheless, more studies should be included to appraise the exact relevance of this gene to prostate cancer.
Materials and methods: In this case-control study, expression of IL-2 and IL-7 was examined in peripheral blood of 40 prostate cancer patients and 40 healthy subjects by reverse transcription quantitative real-time polymerase chain reaction.
Results: Our findings showed that IL-7 has highly elevated expression in patients with prostate cancer compared to healthy subjects (p-value = 0.0001). In contrast, no significant difference was observed in the expression of the IL-2 between the two study groups (p-value = 0.12).
Conclusions: Based on the results, IL-7 may be used as a prospective biomarker or as a molecular target in designing new prostate cancer control strategies. However, the findings of this investigation revealed no association between IL-2 expression and prostate cancer. Nevertheless, more studies should be included to appraise the exact relevance of this gene to prostate cancer.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
